Valdoxan in the Treatment of Depression in Neurological Practice: Results of the Russian Multicenter Naturalistic Study “Resonance”

The efficacy and tolerance of Valdoxan (agomelatine) in mild and moderate depression due to neurological diseases (cerebrovascular pathology, neurocirculatory dystonia, chronic pain) were studied. A total of 227 patients aged 18–70 (mean 46.0 ± 11.3) years were studied, including 21.66 % men and 76....

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2013-11, Vol.43 (9), p.1126-1131
Main Author: Vorob’eva, O. V.
Format: Article
Language:English
Subjects:
Antidepressants
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Chronic pain
Disease
Dystonia
Fatigue
Mental depression
Neurobiology
Neurosciences
Quality of life
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy and tolerance of Valdoxan (agomelatine) in mild and moderate depression due to neurological diseases (cerebrovascular pathology, neurocirculatory dystonia, chronic pain) were studied. A total of 227 patients aged 18–70 (mean 46.0 ± 11.3) years were studied, including 21.66 % men and 76.53 % women. Patients received Valdoxan for six months. After courses, most patients (81.20 %) showed elimination of depression symptomatology, with regression of fatigue, improvements in ability to work (on specific tests), and normalization of the coefficient of mental stability.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-013-9860-7